Log In
Print
BCIQ
Print
Print this Print this
 

CVac

Also known as: Mannan/MUC-1 vaccine

  Manage Alerts
Collapse Summary General Information
Company Prima BioMed Ltd.
DescriptionEx vivo cancer vaccine using a patient's own dendritic cells primed with the tumor antigen mucin 1 (MUC1; CD227) and a mannan-fusion protein (M-FP)
Molecular Target Mucin 1 (MUC1) (CD227)
Mechanism of ActionVaccine; Immunotherapy
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today